Integra Lifesciences Holdings Corp (NASDAQ:IART) – Stock analysts at Cantor Fitzgerald increased their FY2017 earnings per share (EPS) estimates for shares of Integra Lifesciences in a research report issued to clients and investors on Sunday. Cantor Fitzgerald analyst C. Bijou now forecasts that the life sciences company will earn $1.87 per share for the year, up from their previous forecast of $1.84. Cantor Fitzgerald has a “Neutral” rating and a $52.00 price target on the stock. Cantor Fitzgerald also issued estimates for Integra Lifesciences’ FY2018 earnings at $2.31 EPS.
Other equities research analysts have also issued research reports about the stock. Oppenheimer reissued a “buy” rating on shares of Integra Lifesciences in a report on Thursday, January 11th. Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Jefferies Group reissued a “buy” rating and issued a $58.00 price target on shares of Integra Lifesciences in a report on Thursday, October 12th. UBS Group reissued a “buy” rating and issued a $57.00 price target on shares of Integra Lifesciences in a report on Tuesday, October 31st. Finally, Wells Fargo & Co lowered shares of Integra Lifesciences from an “outperform” rating to a “market perform” rating in a report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. Integra Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $52.70.
In other news, VP Richard D. Gorelick sold 1,500 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the sale, the vice president now owns 21,665 shares in the company, valued at approximately $1,022,371.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.50% of the stock is currently owned by insiders.
Several large investors have recently modified their holdings of the company. Capital Research Global Investors boosted its stake in shares of Integra Lifesciences by 227.0% in the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after purchasing an additional 2,705,488 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Integra Lifesciences during the 2nd quarter worth about $112,068,000. State Street Corp lifted its position in Integra Lifesciences by 5.2% during the 2nd quarter. State Street Corp now owns 1,575,125 shares of the life sciences company’s stock worth $85,860,000 after buying an additional 78,082 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Integra Lifesciences by 9.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,189,870 shares of the life sciences company’s stock worth $64,860,000 after buying an additional 101,092 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its position in Integra Lifesciences by 155.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock worth $55,069,000 after buying an additional 664,000 shares in the last quarter. Institutional investors own 87.63% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.